WHO ICTRP trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug…
NCT04411121 · NIH Clinical Trials · Not recruiting
Key facts
| Trial ID | NCT04411121 |
|---|---|
| Public title | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-risk Head and Neck Cancer |
| Scientific title | Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, HPV-Negative Head and Neck Cancer |
| Primary sponsor | National Cancer Institute (NCI) |
| Registry | NIH Clinical Trials |
| Recruitment status | Not recruiting |
| Study type | Interventional |
| Phase | Phase 2/Phase 3 |
| Countries | United States;Canada;China;Canada;China;United States |
| Conditions | p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7;Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7;Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;Stage… |
| Interventions | Drug: Atezolizumab;Biological: Cetuximab;Drug: Cisplatin;Drug: Docetaxel;Radiation: Intensity-Modulated Radiation Therapy;Other: Laboratory Biomarker Analysis;Other: Quality-of-Life Assessment |
| Registration date | May 30, 2020 |
| Target size | 613 |
| Secondary IDs | NCI-2013-00500;RTOG-1216;RTOG-1216;RTOG-1216;U10CA180868;U10CA021661;NCI-2013-00500 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: